Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,606 public trials 547 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Completed

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

NCT03944057

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Beijing Chao-Yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Guangdong Provincial Peoples Hospital Guangzhou, Guangdong, China
  • Nanfang Hospital Guangzhou, Guangdong, China
View all 17 locations
View Trial Details
Completed

A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

NCT04150289

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • American Health Network Indiana Indianapolis, Indiana, United States
  • Southern Nevada Cancer Research Foundation and Optum Cancer Care Las Vegas, Nevada, United States
  • Oncology Specialists of Charlotte Charlotte, North Carolina, United States
  • Southern Oncology Specialists Huntersville, North Carolina, United States
View Trial Details
Completed

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

NCT04136756

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +21 more
Locations
  • Western Regional Medical Center - CTCA Goodyear, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
View all 13 locations
View Trial Details
Completed

Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients

NCT03001804

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Landeskrankenhaus Kirchdorf Kirchdorf, Austria
  • Klinikum Klagenfurt am Wörthersee Klagenfurt, Austria
  • Kepleruniversitätsklinikum GmbH, Hämatologie und Internistische Onkologie Linz, Austria
  • Ordensklinikum Linz GmbH Elisabethinen Linz, Austria
View Trial Details
Completed

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

NCT04754100

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida Louisville, Kentucky, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Cincinnati Cancer Center Cincinnati, Ohio, United States
View Trial Details
Completed

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01734928

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Southern Cancer Center Mobile, Alabama, United States
  • Arizona Oncology Tucson, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • Alta Bates Comprehensive Cancer Center Berkeley, California, United States
View all 321 locations
View Trial Details

Related conditions